Uploaded bydayalanipriyanka
PPTX, PDF59 views

Reactions in leprosy - Type 1 Type 2 reactions

Reactions In leprosy

Embed presentation

Download to read offline
REACTIONS IN LEPROSY Presenter : Dr. Abinaya S Moderator : Associate Prof Dr. Bobita Boro Commentator : Dr. Himakshi Uzir
INTRODUCTION •Leprosy reactions are immunologically mediated episodes of acute or sub-acute inflammation which interrupt, the relatively uneventful usual chronic course of disease affecting the skin, nerves, mucous membrane and/or other sites. This may occur before, during or following MDT. •It may affect any type of leprosy except the indeterminate type. •Unless promptly and adequately treated, they can result in deformity and disability.
TYPES OF REACTION There are three types of reaction recognized. 1. TYPE 1 REACTION 2. TYPE 2 REACTION OR ERYTHEMA NODOSUM LEPROSUM 3. LUCIO PHENOMENON
IMMUNOPATHOGENESIS OF REACTIONS Most reactional episodes occur while the patient is on multidrug therapy Antibiotic treatment Bacteria killed Antigen released Overactivation of immune system Attempts to clear bacterial antigen Inflammation
GENETIC EXPRESSION (Genetic Polymorphism) T1R T2R 1.TLR1 &2 Increase risk Protection 2.NOD2 Protection Increase risk 3.IL6 Increase risk
CELL TYPE Treg Increase. Controls the exacerbated CMI, with benefial consequenses to the host’. Depleted. Unregulated inflammation thus causes extensive clinical manifestations. Widespread tissue damage Th17 Increased/decreased or unchanged Increase , along with recruitment of neutrophils. T1R T2R
CYTOKINES T1R T2R 1.INFγ- Much higher Hallmark Cytokine levels Cause hyperimmune Partial and transient response augmentation of CMI Clearing of bacilli & Sufficient to result concomitant tissue in antibody and IC damage formation but unable to clear bacilli
T1R T2R 2.IL1β & TNFα- Increase Increase • Initial increase in IL1β may indicate higher susceptibility of reactions after treatment initiation. •TNFα decreases with treatment of reaction with steriods and thalidomide. In ENL its level correlated to disease activity. 3. IL6- Significant increase in ENL, considered biomarker of ENL. Levels decline with treatment. 4.IL-17- Th17 related cytokines, mainly found in ENL. IL-17F increases in T1R, while IL-17A increases in ENL.
5. OTHERS- TGFβ , Treg promoter cytokine expressed in ENL. IL10 levels decreases in T1R, increases in ENL. IL2 increase in both. IP10 increase in T1R. ACUTE PHASE REACTANT- CRP raised in T1R mainly while Pentrexin family member PTX3 increases in ENL.
In T1R • Caused by increase in CMI ,i.e. delayed hypersensitivity reaction to M.leprae antigen in skin (presented by macrophages) and nerves (presented by schwann cells). • Activation of CD 4+ lymphocytes (Th1 type) and increased expression of adhesion molecules on endothelium, increased IL-2 and INF-γ leading to increased lymphocytic infiltration in skin and nerves (clinically manifesting as inflamed skin lesions, neuritis, nerve damage) • Hypersensitivity is directed against –cytoplasmic antigens in nerves and surface antigens in skin
In T2R Both humoral and cell mediated mechanisms operate principal event–deposition of antigen- antibody complex in tissues. In LL-most are CD8+ cells, but when ENL starts Macrophages present M. leprae antigens Infiltration of CD4+ cells into dermis Growth factors for mast cells, IL-4, IL-5, IL-10 Stimulate antibody release Immune complex deposition takes place Complement stimulation Neutrophils chemotaxis, TNF-α levels increased Fever and tissue damage
IMMUNOPATHOGENESIS OF NERVE DAMAGE INNATE IMMUNITY- • Human Schwann cells express TLR2. (TLR2 positive leprosy lesions undergo apoptosis ultimately leading to nerve damage). ADAPTIVE IMMUNITY- •TNFα alone does not have toxic effects on schwann cells but in combination with TGFβ leads to significant schwann cell detachment and lysis. •Infected schwann cells process and present antigen of M.leprae to antigen specific inflammatory Th1 cells which damage and lyse the infected schwann cells. (role of CD4cells is more important as compared to CD8)
MECHANISM OF NERVE DAMAGE IN T1R Edema Perineurium(rigid layer) Axonal compression Pressure on venules Interruption of intra-axonal flow Engorgement of capillaries by back pressure venostatic edema - Diffuse subacute and chronic segmental demyelination.
Mechanism of nerve damage due to local edema and granuloma in type I reaction and consequential fibrosis Fibrosis
TYPE 1 REACTION (T1R)  T1R is a delayed hypersensitivity reaction associated with sudden alteration of cell mediated immunity associated with a shift in patient’s position on leprosy spectrum.  Antigens from degenerating leprosy bacilli interact with T lymphocyte and this is associated with rapid change in cell mediated immunity.  It is typically seen a borderline patients because of their immunological instability, rarely seen in LL.
Can be of two types- 1) UPGRADING OR REVERSAL REACTION: Reaction is associated with rapid increase in cell mediated immunity, as seen in patients under treatment. There is shift towards the tuberculoid pole. 2) DOWNGRADING REACTION: Reaction is associated with reduction in immunity. There is shift towards leprematous pole.
EPIDEMIOLOGY OF T1R  Cumulative prevalence varies from 8%-33% for all leprosy patient.  Likely time of occurrence of upgrading reaction-  BT & BB- 2weeks to 6months of treatment  BL-50% will get T1R, usually between 2-12months after starting chemotherapy.  Untreated BT patients suffer from episodes of downgrading reactions reaching BL where the reaction ceases. But likely to occur during chemotherapy.  Upgrading reaction occurs in subpolar LL under treatment, with new skin lesions having features of BL.  T1R can be seen even after treatment and recurrence is common.
RISK FACTORS FOR T1R •During MDT and subsequent 6 months •Positive BI (MB cases) •Extensive disease indicated by the body area involved •Borderline classification- BB & BL have higher risk •Nerve function impairment •Having a facial patch, high risk for lagophthalmos •Pregnancy and delivery( esp 1st 6months after delivery) •Bactericidal drug regimens •Enlarged ulnar nerve at diagnosis •Attending as a self-reporting case •Presence of anti PGL-1 ( Phenolic glycolipid -1) antibodies and lepromin test •BCG vaccination
HISTOPATHOLOGY 1.PRODROMAL PHASE 2.ACTIVE STAGE 3.NECROSIS 4.SUBSIDENCE OEDEMA Mild oedema Severe oedema Profuse oedema Reduction in oedema GRANUL OMA Dilated lymphatics and spaces around Dispersion by swelling and disruption Liquifactive necrosis Reformation CELLS Proliferation of fibroblast around granuloma Different type of giant cells inc. Langhans’ –type cells seen Local infiltation by neutrophils Resolving fibrosis
HISTOLOGICAL CLASSIFICATION OF T1R OEDEMA LYMPHO -CYTES MACRO- PHAGES GIANT- CELLS ACID FAST BACILLI UPGRADING REACTION Intense oedema Markedly increase Old foamy macrophages Many Langhans’ giant cells Decrease or disappear in BL cases DOWN- GRADING REACTION Present Decrease Increase Preexisting ones persist May increase if downgrade d to LL
A) Focus of necrosis within epitheloid cell granuloma in BT leprosy with T1R. B) langhan giant cell and foreign body giant cell with beginning of necrosis.
CLINICAL FEATURES Clinically the most prominent sign is rapidly developing change in the appearance of some or all skin lesions- Which becomes erythematous, edematous, more prominent ,shiny and warm to touch. Necrosis and ulceration may supervene.  Crops of freshly inflamed skin lesions in the form of plaques over previously clinically uninvolved skin (as part of an upgrading reaction in borderline leprosy).  New lesions may appear commonly in downgrading reaction.  Edema of hands, feet and face.  Systemic disturbance like fever and malaise are unusual.
 Rapid swelling with severe pain/tenderness at the site of nerve swelling, and sometimes may be associated with abscess formation.  Sensory nerve involvement could lead to pain in the region of the skin where it supplies ( eg. Pain at medial border of wrist or little finger in cases of ulanr nerve involvement).  Motor disturbance : more serious. Nerves most at risk are ulnar nerve (claw hand), lateral popliteal nerve ( dropped foot) and facial nerve (facial palsy).  These paralyses are likely to be permanent if neglected or incorrectly treated, but will recover with correct and prompt treatment.
A)Type I reaction in a case of borderline tuberculoid (BT) leprosy, B)In a case of borderline borderline (BB) leprosy
Type 1 reaction involving the facial plaque
Left- BT downgrading to BL with T1R Right- After treatment for 2 weeks
Grading of Reversal Reactions  Mild Few skin lesions with features of reaction clinically; without any nerve pain or loss of function. Severe Nerve pain or paraesthesia Increasing loss of nerve function Fever or discomfort Edema of hands, feet Mild reaction persisting for more than 6 weeks Reaction of skin lesion on the face Ulcerative skin lesion
MAJOR Pre-existing and/or new skin lesions become inflamed, red and swollen MINOR •One or more nerves become tender and may be swollen •Crops of new (painless) lesions appear. •Sudden oedema of face and extremities •Recent loss of sensation in hands and feet or signs of recent nerve damage (loss of sweating, sensation, muscle strength) in an area supplied by a particular nerve Diagnosis  Clinical  Criteria -Proposed by Naafs and his team Requires presence of 1 major criterion, or atleast 2 minor criteria (without signs of ENL)
MANAGEMENT •The principles of management of T1R are two folds- 1. Initiation of anti-mycobacterial therapy 2. Administering an effective and prolonged anti-inflammatory therapy with physical support during phase of active neuritis ( if present ) SPECIFIC TREATMENT- 1.CORTICOSTERIODS- Cornerstone of therapy and are considered the drug of choice. •Initial dose of prednisolone- May vary from 40 to 60 mg ( 1mg/kg) •Tapering of steriod- Once improvement is noted, dose is tapered by 5mg every 1-2 weeks until 20mg is reached.
•This dose is continued for few months as gradual improvement in nerve function occurs. After this the steriod is withdrawn at 5mg per fortnight. •Duration- BT- 4-9months BB- 6-9 months BL - 6-18 months, at times 24 months Response- patients with recent NFI <6 months, BL spectrum and medial nerve damage are predictive of favourable response.
2. Alternate drug- i. Azathioprine: in combination with steroid, help reduce the dose of steroids. ii. Methotrexate: Low dose (5-7.5 mg/week) helps in reducing the dose of steroid in patients with steroid intolerance. iii. Cyclosporine A: Useful in cases with chronic neuritis which do not respond well to prednisolone. Started at 5mg/kg/day followed by gradual reduction of the dose. Can be administered for upto 12 months without significant side effects. 3. Immunological drugs- IL-1inhibitor viz. anakinra, rilonacept, canakinumab. Tacrolimus and IL6 inhibiter tocilizumab are being efficacious in studies.
4.Additional measures When acute phase over : •Passive and active exercises •Oil massage, Short wave diathermy, Ultrasonic therapy Surgical decompression : •If despite all the above measures, pain and nerve function impairment continues. Involves exposing the affected nerve trunk at the point of maximal thickness, and giving longitudinal incisions into the nerve upto epineurium layers of nerve bundle.
NERVE ABSCESS IN T1R  The inflammatory response in nerve due to rapid increase in CMI response leads to sudden influx of T lymphocytes into the intraneural granuloma.  In severe reaction process, nerve abscess formation occurs in the affected nerve.  This abscess is predominantly composed of lymphocytes hence, akin to ‘cold abscess’ of Tb, but extremely tender.  TREATMENT- MDT, steroids, Incision and drainage and nerve exploration, epineurotomy or neurectomy.
TYPE 2 REACTION o Also known as Erythema Nodosum Leprosum (ENL). o It is an immune complex syndrome (antigen-antibody reaction involving complement), causing inflammation of skin, nerves and other organs, and generally malaise. o Occurs mostly in LL and sometimes in BL. o Patients with high bacillary index are more prone. o Time of onset : occurs mostly during the course of anti-leprosy treatment. Few cases may present for the first time with features of reaction.
RISK FACTORS •Lepromatous leprosy spectrum with skin infiltration with Bacterial index of >4+ •Anti-leprosy drugs except clofazimine •Patients with <40years of age •Coinfection ( like HIV , TB, Hep B &C, typhoid etc) •Intercurrent infections •Trauma or Surgical intervention •Physical and mental stress •Protective immunizations •A strongly positive Mantoux test •Pregnancy and parturition •Decrease C4 and elevated anti M.leprae antibodies in newly diagnosed case •Ingestion of potassium iodide
Epidemiology  Average incidence of ENL in LL cases is about 15.4% ( 11.1 – 26%), and in BL 4.1% (2.7-5.1%)  Most commonly occurs after 6 months of MDT, but in 1/3rd patients appear as presenting symptoms without treatment.  It may occur even after MDT (upto 7-8 years) due to persistence of bacterial antigens.
Histology 1.Granuloma made of foamy macrophages, many of which are filled with M.leprae 2.Neutrophilic infiltrate 3.Swelling of endothelial cells and edema of vessel walls 4.Acute necrotizing vasculitis—variable finding 5.Necrotizing ENL—same findings but in greater degree—more severe and widespread 6.Bacilli are fragmented and granular. As reaction subsides—lymphocytes and plasma cells increase and neutrophils decrease Resolution occurs with fibrosis.
A)Macrophage granuloma in LL with T2R B)Higher magnification showing neutrophillic infiltation in macrophage garnuloma
CLINICAL FEATURES  Type 2 reaction can cause inflammation in any organ invaded by lepra bacilli  Cutaneous lesions-presents as crops of erythematous partially blanchable, warm, tender papules or nodules. These may be superficial or deep seated and have b/l symmetrical predilection.  The lesions are evanecent lasting for 2-3 days and multiple in number.  Usual sites are face, arms, thighs, palms and soles and may appear in any area except hairy scalp axilla, groin and perineum.
 The fresh crops of ENL lesions and intermittent fever usually appear in the evening when endogenous cortisol production is at its lowest.  In SEVERE cases, skin lesions may become pustular, ulcerated, hemorrhagic, necrotic , vesicular, bullous, Sweet Syndrome like and erythema multiforme-like.  Generalized systemic illness, associated with fever, myalgia, edema of face, hands and feet and loss of protein in urine are present in T2R.  Fever is considered the hallmark of ENL
Erythema nodosum leprosum (ENL) in a case of LL
Pustular ENL Necroticoulcerative lesion in ENL Erythema multiforme type of ENL
ORGANS SIGNS AND SYMPTOMS JOINTS Polyathritis /polyarthalgia, with pain, tenderness and limitation of movement mainly affecting knee, MCP,IP, Wrist & ankle jt. LYMPH NODES Acute and tender lymphadenopathy esp femoral, inguinal, axillary, cervical and epitrochlear LN EYES Conjunctivitis, iritis, iridocyclitis, glaucoma and blindness LIVER Hepatomegaly , soft and tender GENITILIA Epididymo-orchitis- repeated reaction can lead to testicular atrophy and gynaecomastia KIDNEYS Glomerulonephitis, acute tubulointerstitial nephritis, amylodosis- which can progress to CKD BONE Dactylitis , periosteitis MUSCLES Myalgia, myositis NERVES Neuritis
DIAGNOSIS  Clinical Clinical tests : -Ryrie test : stroking of sole of foot with the back of a reflex hammer elicits a burning pain. -Ellis test : Squeezing the wrist during ENL elicits a painful reaction.  Histopathology  Laboratory tests -Haematological changes : leucocytosis, increased ESR and CRP -Urine may show presence of albumin, RBC, pus cells, epithelial cells and casts. -LFT : there may be rise in serum bilirubin and transaminases (SGOT, SGPT)
CRITERIA FOR DIAGNOSIS OF T2R •Proposed by B Naafs and his team •There should be presence of atleast 1 major criterion or 3 minor criteria Major criteria A sudden eruption of tender red papules, nodules or plaques which may ulcerate Minor criteria  Mild fever , the patient is unwell  Tender enlarged nerves  Increased loss of sensation and muscle power  Arthritis  Lymphadenitis  Epididymo-orchitis  Iridocyclitis or episcleritis  Edema of extermity or face  Positive Ryrie’s test or Ellis’ test
MANAGEMENT GENERAL MEASURES- •Treat precipitating factors : -Intercurrent infections -Psychological stress. •Continue or start MDT. SPECIFIC MEASURES- 1.MILD T2R- analgesics such as aspirin, indomethacin, ibuprofen, diclofenac, paracetamol. Monitoring should be done every 2 weeks. If there is worsening and increase in symptoms, it is treated as severe. 2.MODERATE T2R- steriod is used at a dose of 30-40mg prednisolone/day. 3.RECURRENT T2R- increase and prolonged dose of steriods to control the inflammation and symptoms.
TREATMENT ALGORITHM FOR MANAGEMENT OF T2R
1. CORTICOSTERIOD: • 1st line treatment in severe ENL •Useful in- 1.neuritis when muscle paralysis threatened 2. iritis not responding to topical steriods 3. presence of epididymo-orchitis 4. in erythema necroticans( vesicular/bullous ENL) •Dose- 1-1.5mg/kg/day for 2-4 weeks -then tapering by 10mg every 2weeks till 20mg per day. -Then slow tapering of 5mg every 2weeks. •Patient requires steriods for long time due to reccurent and chronic nature of ENL
2.THALIDOMIDE: •Treatment of choice,but kept as 2nd choice due to its teratogenic effects, difficulty in monitoring , high cost and non availability at places •MOA- 1. Inhibition of TNFα and neutrophil recruitment 2.polarization of immune response towards Th2 with production of IL2 , IL4 and 5. 3. suppresion of formation of IgM antibodies 4. decrease T helper cells and increased suppressor T cell production. •DOSE- 3-4 tabs of 100mg daily in divided doses, tailing of as reaction subsides. -continue 1tab daily or alternate day to avoid outbreaks
3. CLOFAZIMINE: •High doses of clofazimine has anti inflammatory property. •DOSE- 100 mg thrice daily along with standard course of prednisolone and to continue for a maximum of 12 weeks. - tapering of dose is 100mg twice daily for 12 weeks then 100mg once daily for 12-24 weeks. •It is slow to act and takes about 4-6 weeks to act. However it helps in reduction of dose of steriod. •Management with clofazimine alone is indicated in patient where steriods are CI.
ALTERNATE OPTIONS- 1. Azathioprine – Good steriod sparing agent. It interferes with purine production , also has anti- TNFα action. - effective dose is 2mg/kg/day given for 6-8 months. 2. Methotrexate- useful in recalcitrant cases and chronic steriod resistant ENL. 3. TNFα Inhibitors- Infliximab and etanercept. - useful in resistant recurrent ENL cases which fail to respond to prednisolone. - DOSE -INFLIXIMAB at a dose of 5mg/kg, repeated dosage given on week 2 and 6. -ETANERCEPT at a dose of 50mg/week given sc
4.Minocycline- has anti-inflammatory and anti- apoptotic properties. Useful in reccurent and/or chronic cases. - main advantage of using antibacterials like minocycline and clofazimine are additional immunomodulatory, anti-inflammatory and neuroprotective action. 5. Aprimilast- oral phosphodiesterase-4 inhibitor have immunomodulatory and anti-inflammatory actions. Inhibits proinflammatory cytokines involved in T2R. 6.Leprosy Vaccine
DIFFERENCES BETWEEN T1R AND T2R FEATURES T1R T2R Type of immunological reaction Delayed type of HS reaction(type IV) Antigen antibody IC reaction (type III) Type of patient affected Borderline type (BT, BB, BL, rarely subpolar LL) LL, rarely BL Constitutional signs and symptoms None or rare Common Type of skin lesions Existing skin lesions suddenly become reddish, swollen, warm, painful, tender Fresh red, painful, tender, subcutaneous nodules, plaques.Existing skin lesions remain unchanged Nerve involvement Nerves close to skin lesions may become enlarged, painful and tender due to acute neuritis with loss of nerve function Nerves may be affected but not as common or as severe as T1R Eye involvement Corneal anaesthesia and lagophthalmos may occur due to nerve involvement Internal eye diseases like iritis, iridocyclitis, glaucoma are common Other organs Not affected May be affected(lymphadenitis, epididymo-orchitis, arthritis)
LUCIO PHENOMENON •This is a unique form of leprosy reaction, which occurs due to massive proliferation of lepra bacilli inside endothelial cells resulting in vascular occlusion and vasculitis. •It occurs 3-4 years after onset of disease. • It is more common in - untreated patients with diffuse LL -in those who received inadequate treatment. •It presents with minimal systemic features and neuritis.
LESIONS Painful, tender, red patch, with a geographic margin Becomes purpuric Center becomes necrotic and ulcerate Develops brown or black crust (eschar) Falls off after few days to leave a superficial atrophic scar
ETIOPATHOGENESIS Patients in lucio phenomenon has a singularly deficient defense mechanism Which permits unhindered multiplication of bacteria Exposure of bacterial antigen to circulating antibody Vasculitis, thrombosis, infarction and skin necrosis HISTOLOGY - Ischaemic epidermal necrosis, •Fibrin thrombi in vessel lumen with wall infiltration, necrotising vasculitis of small and medium blood vessels in the upper dermis •severe focal endothelial proliferation of mid-dermal vessels •presence of large number of AFB in endothelial cells.
CLINICAL FEATURE •Patient is usually afebrile •Appearance of erythematous diffuse or plaque type lesions which becomes purpuric, becomes necrotic followed by black eschar formation. •The lesions mainly appear on the extremities and spreads in a characteristic ascending fashion. •The lesions are frequently described as triangular, polygonal or angular ulcers. •Occasionally hemorrhagic blisters and edema of hands, feet and ear conchae have been described •Usually patient have lesions which are on different stages of evolution. TREATMENT • MDT should be started. • Respond well to oral steroids. Do not respond to thalidomide .
Lucio Phenomenon
LUCIO PHENOMENON Vs T2R WITH VASCULONECROTIC PHENOMENON FEATURES LUCIO PHENOMENON NECROTIZING ENL Seen in Diffuse LL BL, LL Patient status Untreated Treated Clinical features Angular geographic necrotic lesions, ulcers,heals with scar Generalized Painful nodules with necrosis Histology Inv. of medium sized vessels of mid dermis with thrombosis and endothelial proliferation. Necrotizing vasculitis of small blood vessels of superficial dermis Panvasculitis starts in hypodermis with larger deep necrosis resulting in fibrotic scar. General symptoms No general symptoms Systemic features with fever seen Neuritis Absent Marked Mainly vasculopathy Vasculitis
LAZARINE LEPROSY It is ulcerating type 1 reaction •Found in BT Hansen with spontaneous ulceration, occuring due to extreme hypersensitivity in type 1 reaction •Factors implicated- breakdown of local immunity, increase proliferation of bacilli and severe tissue edema. •Concomitant secondary infection due to protein malnutrition have also been implicated. •There is no localized skin infiltrations. •Systemic corticosteriods are necessary.
Multiple non tender ulcers appearing on pre-existing lesion of chest and back
THANK YOU

More Related Content

PPTX
Anatomy and physiology of sebaceous glands.pptx
byMayuriMotgi
 
PPT
Basic immunology from the dermatologic point of view(innate)
byHima Farag
 
PDF
Phototherapy
byDR RML DELHI
 
PPT
Drugs and the skin satya. 2014 ppt
bysathyanarayanan varadarajan
 
PPT
Apocrine and eccrine glands
bySmruti Ramawanshi
 
PPT
Alta Frecuencia
byundiamaaas
 
PPTX
Skin Photobiology and Photoimmunology ppt
byDr Anand
 
PPTX
Apocrine and eccrine glands
bydocjikisha
 
Anatomy and physiology of sebaceous glands.pptx
byMayuriMotgi
 
Basic immunology from the dermatologic point of view(innate)
byHima Farag
 
Phototherapy
byDR RML DELHI
 
Drugs and the skin satya. 2014 ppt
bysathyanarayanan varadarajan
 
Apocrine and eccrine glands
bySmruti Ramawanshi
 
Alta Frecuencia
byundiamaaas
 
Skin Photobiology and Photoimmunology ppt
byDr Anand
 
Apocrine and eccrine glands
bydocjikisha
 

What's hot

PPTX
Lepra reactions ketki.pptx
byDeepikaKothari9
 
PPTX
Inflammation part 1
byRuchika Garg
 
PPTX
Hydroxychloroquine in Dermatology.pptx
byDRKIMkhan
 
PPTX
Leprosy
bypunit patel
 
PPTX
SJS/TEN
byVinuthna Chowdary
 
PPTX
Bacteriology & Immunology of Leprosy
byJerriton Brewin
 
PPTX
Tratamientos Corporales
byhildacuadras
 
PPT
Acute inflammation
byDr Snehal Kosale
 
PPTX
Skin .pptx
byPavan Jagtap
 
PDF
Skeyndor power retinol
byskeyndoruk
 
PPTX
Introduction of Human skin
byShivanshuGangwar
 
PPT
Archer Dermatology USMLE step 3
byArcher Review USMLE and NCLEX
 
PPTX
Sebaceous gland.pptx
bysriramck2
 
PPT
Chapter 16
byJacqueline Farcas
 
PPTX
Glands in skin | Skin Specialist in Zirakpur | Dr. Isha V.Mittal | +91-72-93-...
byDr. Isha V.Mittal
 
PPT
Microdermoabrasión
byhannia7
 
PPTX
Overview of hyperpigmentation disorders
bypeternugraha
 
PPTX
Melasma
byHassan Al Sa
 
PPTX
Anatomy & physiology of sweat glands, sebaceous
byAhmed Amer
 
PPTX
Stains in dermatology
byBayan Matarneh
 
Lepra reactions ketki.pptx
byDeepikaKothari9
 
Inflammation part 1
byRuchika Garg
 
Hydroxychloroquine in Dermatology.pptx
byDRKIMkhan
 
Leprosy
bypunit patel
 
SJS/TEN
byVinuthna Chowdary
 
Bacteriology & Immunology of Leprosy
byJerriton Brewin
 
Tratamientos Corporales
byhildacuadras
 
Acute inflammation
byDr Snehal Kosale
 
Skin .pptx
byPavan Jagtap
 
Skeyndor power retinol
byskeyndoruk
 
Introduction of Human skin
byShivanshuGangwar
 
Archer Dermatology USMLE step 3
byArcher Review USMLE and NCLEX
 
Sebaceous gland.pptx
bysriramck2
 
Chapter 16
byJacqueline Farcas
 
Glands in skin | Skin Specialist in Zirakpur | Dr. Isha V.Mittal | +91-72-93-...
byDr. Isha V.Mittal
 
Microdermoabrasión
byhannia7
 
Overview of hyperpigmentation disorders
bypeternugraha
 
Melasma
byHassan Al Sa
 
Anatomy & physiology of sweat glands, sebaceous
byAhmed Amer
 
Stains in dermatology
byBayan Matarneh
 

Similar to Reactions in leprosy - Type 1 Type 2 reactions

PPTX
Leprosy
byPratik Kumar
 
PDF
Leprosy microbiology
bySaachiGupta4
 
PDF
Lepra reactions
byDR RML DELHI
 
PPTX
Leprosy
byGSL medical college
 
PPTX
Relapse,reactivation,reactionsof leprosy.pptx
byLavanyaCool
 
PPTX
Hansen disease by sandra gboneme
bySandra Gboneme
 
PPTX
Leprosy
bydrsapnaharsha
 
PPTX
Lepra Reaction. By dr Sarabjeet Singh .pptx
bydrsarab1393
 
PPTX
Leprosy, DTU.pptxvnjkkkllooigfdddddfuuiiiii
byhussenuki
 
PPTX
Lepra reactions
byDr ABU SURAIH SAKHRI
 
PPTX
Typical and atypical manifestations of leprosy
byChetan Ganteppanavar
 
PPTX
leprosy - immuno n histo.pptx dermatology slide
byNirmalaAyuzawa
 
PPTX
Leprosy, its types, causes, symptoms and treatment
bysabawaseem8687
 
PPTX
Leprosy
byDr Subodh Shah
 
PPT
10Leprosy.powerpoints for healthy studen
byGatluaklampal
 
PPT
leprosy caused by Mycobacterium leprae bact
byMohd Azam
 
PDF
Tables in dermatology updates 2025.pdf
byHany salah Soliman
 
PPTX
01 ahmed omar leprosy -last edition
byAhmed Omar
 
PDF
Reactions after 1 and 2 year mdt
byred de salud del oriente
 
PPT
Brief description on "Leprosy" Reactions
byAndargeImperial
 
Leprosy
byPratik Kumar
 
Leprosy microbiology
bySaachiGupta4
 
Lepra reactions
byDR RML DELHI
 
Leprosy
byGSL medical college
 
Relapse,reactivation,reactionsof leprosy.pptx
byLavanyaCool
 
Hansen disease by sandra gboneme
bySandra Gboneme
 
Leprosy
bydrsapnaharsha
 
Lepra Reaction. By dr Sarabjeet Singh .pptx
bydrsarab1393
 
Leprosy, DTU.pptxvnjkkkllooigfdddddfuuiiiii
byhussenuki
 
Lepra reactions
byDr ABU SURAIH SAKHRI
 
Typical and atypical manifestations of leprosy
byChetan Ganteppanavar
 
leprosy - immuno n histo.pptx dermatology slide
byNirmalaAyuzawa
 
Leprosy, its types, causes, symptoms and treatment
bysabawaseem8687
 
Leprosy
byDr Subodh Shah
 
10Leprosy.powerpoints for healthy studen
byGatluaklampal
 
leprosy caused by Mycobacterium leprae bact
byMohd Azam
 
Tables in dermatology updates 2025.pdf
byHany salah Soliman
 
01 ahmed omar leprosy -last edition
byAhmed Omar
 
Reactions after 1 and 2 year mdt
byred de salud del oriente
 
Brief description on "Leprosy" Reactions
byAndargeImperial
 

Recently uploaded

PPTX
ATTENTION - PART 1.pptx cognitive processes -For B.Sc I Sem By Mrs.Shilpa Hot...
bySHILPA HOTAKAR
 
PPTX
Declaration of Helsinki Basic principles in medical research ppt.pptx
byRanikonde
 
PPTX
Anatomy of the eyeball An overviews.pptx
byMushahidRaza8
 
PPTX
Psychological disorders affecting students well being.pptx
bymunushah
 
PDF
Celebrating International Project Management Day with AECOM
byAssociation for Project Management
 
PPTX
PPT MA 8 WEEK 3-4.pptx Music and Arts Grade 8
byEdenGraceLopez1
 
PPTX
ENGLISH3 PPT WEEK-3-QUARTER-3 day 1.pptx
byjocelynpamintuan001
 
PPTX
Time Series Analysis - Least Square Method Fitting a Linear Trend Equation
bySundar B N
 
PDF
Gemini Study Jams 2025 - GDGoC FPTU event
byminhtrietgect
 
PPTX
Appreciations - Nov 25.pptxjkjjkjjkjejfkejfkjekjekjkjekjekjkjekjktejektj
bypreetheshparmar
 
PDF
What is Digital Engineering, and how can it be used to enhance Project Manage...
byAssociation for Project Management
 
PDF
Conferencia de Abertura_Virgilio Almeida.pdf
byGrupo Tordesillas
 
PPTX
English 5 Q3 W3 Describing the Character Traits Using Literal or Implied Mean...
byAizaPanganiban3
 
PPTX
How to create a Pass-Fail quality check in Odoo 18 Quality
byCeline George
 
PDF
Digital Journalism Ethics 2025 materi for Regulation & Ethic Media
byAdePutraTunggali
 
PDF
DIFFRENCE BETWEEN SOCIETY AND COMMUNITY.pdf
byJhasketan Kuanar
 
PPTX
How to Analyze Employee Retention Rate in Odoo 18
byCeline George
 
PPTX
Time Series Analysis - Seasonal Indices by the Ratio to Trend Method
bySundar B N
 
PPTX
An Complete Overview of Chatter in Odoo 18
byCeline George
 
PPTX
Time Series Analysis - Weighted (Unequal) Moving Average Method
bySundar B N
 
ATTENTION - PART 1.pptx cognitive processes -For B.Sc I Sem By Mrs.Shilpa Hot...
bySHILPA HOTAKAR
 
Declaration of Helsinki Basic principles in medical research ppt.pptx
byRanikonde
 
Anatomy of the eyeball An overviews.pptx
byMushahidRaza8
 
Psychological disorders affecting students well being.pptx
bymunushah
 
Celebrating International Project Management Day with AECOM
byAssociation for Project Management
 
PPT MA 8 WEEK 3-4.pptx Music and Arts Grade 8
byEdenGraceLopez1
 
ENGLISH3 PPT WEEK-3-QUARTER-3 day 1.pptx
byjocelynpamintuan001
 
Time Series Analysis - Least Square Method Fitting a Linear Trend Equation
bySundar B N
 
Gemini Study Jams 2025 - GDGoC FPTU event
byminhtrietgect
 
Appreciations - Nov 25.pptxjkjjkjjkjejfkejfkjekjekjkjekjekjkjekjktejektj
bypreetheshparmar
 
What is Digital Engineering, and how can it be used to enhance Project Manage...
byAssociation for Project Management
 
Conferencia de Abertura_Virgilio Almeida.pdf
byGrupo Tordesillas
 
English 5 Q3 W3 Describing the Character Traits Using Literal or Implied Mean...
byAizaPanganiban3
 
How to create a Pass-Fail quality check in Odoo 18 Quality
byCeline George
 
Digital Journalism Ethics 2025 materi for Regulation & Ethic Media
byAdePutraTunggali
 
DIFFRENCE BETWEEN SOCIETY AND COMMUNITY.pdf
byJhasketan Kuanar
 
How to Analyze Employee Retention Rate in Odoo 18
byCeline George
 
Time Series Analysis - Seasonal Indices by the Ratio to Trend Method
bySundar B N
 
An Complete Overview of Chatter in Odoo 18
byCeline George
 
Time Series Analysis - Weighted (Unequal) Moving Average Method
bySundar B N
 

Reactions in leprosy - Type 1 Type 2 reactions

  • 1.
    REACTIONS IN LEPROSY Presenter: Dr. Abinaya S Moderator : Associate Prof Dr. Bobita Boro Commentator : Dr. Himakshi Uzir
  • 2.
    INTRODUCTION •Leprosy reactions areimmunologically mediated episodes of acute or sub-acute inflammation which interrupt, the relatively uneventful usual chronic course of disease affecting the skin, nerves, mucous membrane and/or other sites. This may occur before, during or following MDT. •It may affect any type of leprosy except the indeterminate type. •Unless promptly and adequately treated, they can result in deformity and disability.
  • 3.
    TYPES OF REACTION Thereare three types of reaction recognized. 1. TYPE 1 REACTION 2. TYPE 2 REACTION OR ERYTHEMA NODOSUM LEPROSUM 3. LUCIO PHENOMENON
  • 4.
    IMMUNOPATHOGENESIS OF REACTIONS Mostreactional episodes occur while the patient is on multidrug therapy Antibiotic treatment Bacteria killed Antigen released Overactivation of immune system Attempts to clear bacterial antigen Inflammation
  • 5.
    GENETIC EXPRESSION (GeneticPolymorphism) T1R T2R 1.TLR1 &2 Increase risk Protection 2.NOD2 Protection Increase risk 3.IL6 Increase risk
  • 6.
    CELL TYPE Treg Increase. Controlsthe exacerbated CMI, with benefial consequenses to the host’. Depleted. Unregulated inflammation thus causes extensive clinical manifestations. Widespread tissue damage Th17 Increased/decreased or unchanged Increase , along with recruitment of neutrophils. T1R T2R
  • 7.
    CYTOKINES T1R T2R 1.INFγ- Muchhigher Hallmark Cytokine levels Cause hyperimmune Partial and transient response augmentation of CMI Clearing of bacilli & Sufficient to result concomitant tissue in antibody and IC damage formation but unable to clear bacilli
  • 8.
    T1R T2R 2.IL1β &TNFα- Increase Increase • Initial increase in IL1β may indicate higher susceptibility of reactions after treatment initiation. •TNFα decreases with treatment of reaction with steriods and thalidomide. In ENL its level correlated to disease activity. 3. IL6- Significant increase in ENL, considered biomarker of ENL. Levels decline with treatment. 4.IL-17- Th17 related cytokines, mainly found in ENL. IL-17F increases in T1R, while IL-17A increases in ENL.
  • 9.
    5. OTHERS- TGFβ, Treg promoter cytokine expressed in ENL. IL10 levels decreases in T1R, increases in ENL. IL2 increase in both. IP10 increase in T1R. ACUTE PHASE REACTANT- CRP raised in T1R mainly while Pentrexin family member PTX3 increases in ENL.
  • 10.
    In T1R • Causedby increase in CMI ,i.e. delayed hypersensitivity reaction to M.leprae antigen in skin (presented by macrophages) and nerves (presented by schwann cells). • Activation of CD 4+ lymphocytes (Th1 type) and increased expression of adhesion molecules on endothelium, increased IL-2 and INF-γ leading to increased lymphocytic infiltration in skin and nerves (clinically manifesting as inflamed skin lesions, neuritis, nerve damage) • Hypersensitivity is directed against –cytoplasmic antigens in nerves and surface antigens in skin
  • 11.
    In T2R Both humoraland cell mediated mechanisms operate principal event–deposition of antigen- antibody complex in tissues. In LL-most are CD8+ cells, but when ENL starts Macrophages present M. leprae antigens Infiltration of CD4+ cells into dermis Growth factors for mast cells, IL-4, IL-5, IL-10 Stimulate antibody release Immune complex deposition takes place Complement stimulation Neutrophils chemotaxis, TNF-α levels increased Fever and tissue damage
  • 12.
    IMMUNOPATHOGENESIS OF NERVEDAMAGE INNATE IMMUNITY- • Human Schwann cells express TLR2. (TLR2 positive leprosy lesions undergo apoptosis ultimately leading to nerve damage). ADAPTIVE IMMUNITY- •TNFα alone does not have toxic effects on schwann cells but in combination with TGFβ leads to significant schwann cell detachment and lysis. •Infected schwann cells process and present antigen of M.leprae to antigen specific inflammatory Th1 cells which damage and lyse the infected schwann cells. (role of CD4cells is more important as compared to CD8)
  • 13.
    MECHANISM OF NERVEDAMAGE IN T1R Edema Perineurium(rigid layer) Axonal compression Pressure on venules Interruption of intra-axonal flow Engorgement of capillaries by back pressure venostatic edema - Diffuse subacute and chronic segmental demyelination.
  • 14.
    Mechanism of nervedamage due to local edema and granuloma in type I reaction and consequential fibrosis Fibrosis
  • 15.
    TYPE 1 REACTION(T1R)  T1R is a delayed hypersensitivity reaction associated with sudden alteration of cell mediated immunity associated with a shift in patient’s position on leprosy spectrum.  Antigens from degenerating leprosy bacilli interact with T lymphocyte and this is associated with rapid change in cell mediated immunity.  It is typically seen a borderline patients because of their immunological instability, rarely seen in LL.
  • 16.
    Can be oftwo types- 1) UPGRADING OR REVERSAL REACTION: Reaction is associated with rapid increase in cell mediated immunity, as seen in patients under treatment. There is shift towards the tuberculoid pole. 2) DOWNGRADING REACTION: Reaction is associated with reduction in immunity. There is shift towards leprematous pole.
  • 17.
    EPIDEMIOLOGY OF T1R Cumulative prevalence varies from 8%-33% for all leprosy patient.  Likely time of occurrence of upgrading reaction-  BT & BB- 2weeks to 6months of treatment  BL-50% will get T1R, usually between 2-12months after starting chemotherapy.  Untreated BT patients suffer from episodes of downgrading reactions reaching BL where the reaction ceases. But likely to occur during chemotherapy.  Upgrading reaction occurs in subpolar LL under treatment, with new skin lesions having features of BL.  T1R can be seen even after treatment and recurrence is common.
  • 18.
    RISK FACTORS FORT1R •During MDT and subsequent 6 months •Positive BI (MB cases) •Extensive disease indicated by the body area involved •Borderline classification- BB & BL have higher risk •Nerve function impairment •Having a facial patch, high risk for lagophthalmos •Pregnancy and delivery( esp 1st 6months after delivery) •Bactericidal drug regimens •Enlarged ulnar nerve at diagnosis •Attending as a self-reporting case •Presence of anti PGL-1 ( Phenolic glycolipid -1) antibodies and lepromin test •BCG vaccination
  • 19.
    HISTOPATHOLOGY 1.PRODROMAL PHASE 2.ACTIVE STAGE 3.NECROSIS 4.SUBSIDENCE OEDEMA Mildoedema Severe oedema Profuse oedema Reduction in oedema GRANUL OMA Dilated lymphatics and spaces around Dispersion by swelling and disruption Liquifactive necrosis Reformation CELLS Proliferation of fibroblast around granuloma Different type of giant cells inc. Langhans’ –type cells seen Local infiltation by neutrophils Resolving fibrosis
  • 20.
    HISTOLOGICAL CLASSIFICATION OFT1R OEDEMA LYMPHO -CYTES MACRO- PHAGES GIANT- CELLS ACID FAST BACILLI UPGRADING REACTION Intense oedema Markedly increase Old foamy macrophages Many Langhans’ giant cells Decrease or disappear in BL cases DOWN- GRADING REACTION Present Decrease Increase Preexisting ones persist May increase if downgrade d to LL
  • 21.
    A) Focus ofnecrosis within epitheloid cell granuloma in BT leprosy with T1R. B) langhan giant cell and foreign body giant cell with beginning of necrosis.
  • 22.
    CLINICAL FEATURES Clinically themost prominent sign is rapidly developing change in the appearance of some or all skin lesions- Which becomes erythematous, edematous, more prominent ,shiny and warm to touch. Necrosis and ulceration may supervene.  Crops of freshly inflamed skin lesions in the form of plaques over previously clinically uninvolved skin (as part of an upgrading reaction in borderline leprosy).  New lesions may appear commonly in downgrading reaction.  Edema of hands, feet and face.  Systemic disturbance like fever and malaise are unusual.
  • 23.
     Rapid swellingwith severe pain/tenderness at the site of nerve swelling, and sometimes may be associated with abscess formation.  Sensory nerve involvement could lead to pain in the region of the skin where it supplies ( eg. Pain at medial border of wrist or little finger in cases of ulanr nerve involvement).  Motor disturbance : more serious. Nerves most at risk are ulnar nerve (claw hand), lateral popliteal nerve ( dropped foot) and facial nerve (facial palsy).  These paralyses are likely to be permanent if neglected or incorrectly treated, but will recover with correct and prompt treatment.
  • 24.
    A)Type I reactionin a case of borderline tuberculoid (BT) leprosy, B)In a case of borderline borderline (BB) leprosy
  • 25.
    Type 1 reactioninvolving the facial plaque
  • 26.
    Left- BT downgradingto BL with T1R Right- After treatment for 2 weeks
  • 27.
    Grading of ReversalReactions  Mild Few skin lesions with features of reaction clinically; without any nerve pain or loss of function. Severe Nerve pain or paraesthesia Increasing loss of nerve function Fever or discomfort Edema of hands, feet Mild reaction persisting for more than 6 weeks Reaction of skin lesion on the face Ulcerative skin lesion
  • 28.
    MAJOR Pre-existing and/ornew skin lesions become inflamed, red and swollen MINOR •One or more nerves become tender and may be swollen •Crops of new (painless) lesions appear. •Sudden oedema of face and extremities •Recent loss of sensation in hands and feet or signs of recent nerve damage (loss of sweating, sensation, muscle strength) in an area supplied by a particular nerve Diagnosis  Clinical  Criteria -Proposed by Naafs and his team Requires presence of 1 major criterion, or atleast 2 minor criteria (without signs of ENL)
  • 29.
    MANAGEMENT •The principles ofmanagement of T1R are two folds- 1. Initiation of anti-mycobacterial therapy 2. Administering an effective and prolonged anti-inflammatory therapy with physical support during phase of active neuritis ( if present ) SPECIFIC TREATMENT- 1.CORTICOSTERIODS- Cornerstone of therapy and are considered the drug of choice. •Initial dose of prednisolone- May vary from 40 to 60 mg ( 1mg/kg) •Tapering of steriod- Once improvement is noted, dose is tapered by 5mg every 1-2 weeks until 20mg is reached.
  • 30.
    •This dose iscontinued for few months as gradual improvement in nerve function occurs. After this the steriod is withdrawn at 5mg per fortnight. •Duration- BT- 4-9months BB- 6-9 months BL - 6-18 months, at times 24 months Response- patients with recent NFI <6 months, BL spectrum and medial nerve damage are predictive of favourable response.
  • 31.
    2. Alternate drug- i.Azathioprine: in combination with steroid, help reduce the dose of steroids. ii. Methotrexate: Low dose (5-7.5 mg/week) helps in reducing the dose of steroid in patients with steroid intolerance. iii. Cyclosporine A: Useful in cases with chronic neuritis which do not respond well to prednisolone. Started at 5mg/kg/day followed by gradual reduction of the dose. Can be administered for upto 12 months without significant side effects. 3. Immunological drugs- IL-1inhibitor viz. anakinra, rilonacept, canakinumab. Tacrolimus and IL6 inhibiter tocilizumab are being efficacious in studies.
  • 32.
    4.Additional measures When acutephase over : •Passive and active exercises •Oil massage, Short wave diathermy, Ultrasonic therapy Surgical decompression : •If despite all the above measures, pain and nerve function impairment continues. Involves exposing the affected nerve trunk at the point of maximal thickness, and giving longitudinal incisions into the nerve upto epineurium layers of nerve bundle.
  • 33.
    NERVE ABSCESS INT1R  The inflammatory response in nerve due to rapid increase in CMI response leads to sudden influx of T lymphocytes into the intraneural granuloma.  In severe reaction process, nerve abscess formation occurs in the affected nerve.  This abscess is predominantly composed of lymphocytes hence, akin to ‘cold abscess’ of Tb, but extremely tender.  TREATMENT- MDT, steroids, Incision and drainage and nerve exploration, epineurotomy or neurectomy.
  • 34.
    TYPE 2 REACTION oAlso known as Erythema Nodosum Leprosum (ENL). o It is an immune complex syndrome (antigen-antibody reaction involving complement), causing inflammation of skin, nerves and other organs, and generally malaise. o Occurs mostly in LL and sometimes in BL. o Patients with high bacillary index are more prone. o Time of onset : occurs mostly during the course of anti-leprosy treatment. Few cases may present for the first time with features of reaction.
  • 35.
    RISK FACTORS •Lepromatous leprosyspectrum with skin infiltration with Bacterial index of >4+ •Anti-leprosy drugs except clofazimine •Patients with <40years of age •Coinfection ( like HIV , TB, Hep B &C, typhoid etc) •Intercurrent infections •Trauma or Surgical intervention •Physical and mental stress •Protective immunizations •A strongly positive Mantoux test •Pregnancy and parturition •Decrease C4 and elevated anti M.leprae antibodies in newly diagnosed case •Ingestion of potassium iodide
  • 36.
    Epidemiology  Average incidenceof ENL in LL cases is about 15.4% ( 11.1 – 26%), and in BL 4.1% (2.7-5.1%)  Most commonly occurs after 6 months of MDT, but in 1/3rd patients appear as presenting symptoms without treatment.  It may occur even after MDT (upto 7-8 years) due to persistence of bacterial antigens.
  • 37.
    Histology 1.Granuloma made offoamy macrophages, many of which are filled with M.leprae 2.Neutrophilic infiltrate 3.Swelling of endothelial cells and edema of vessel walls 4.Acute necrotizing vasculitis—variable finding 5.Necrotizing ENL—same findings but in greater degree—more severe and widespread 6.Bacilli are fragmented and granular. As reaction subsides—lymphocytes and plasma cells increase and neutrophils decrease Resolution occurs with fibrosis.
  • 38.
    A)Macrophage granuloma inLL with T2R B)Higher magnification showing neutrophillic infiltation in macrophage garnuloma
  • 39.
    CLINICAL FEATURES  Type2 reaction can cause inflammation in any organ invaded by lepra bacilli  Cutaneous lesions-presents as crops of erythematous partially blanchable, warm, tender papules or nodules. These may be superficial or deep seated and have b/l symmetrical predilection.  The lesions are evanecent lasting for 2-3 days and multiple in number.  Usual sites are face, arms, thighs, palms and soles and may appear in any area except hairy scalp axilla, groin and perineum.
  • 40.
     The freshcrops of ENL lesions and intermittent fever usually appear in the evening when endogenous cortisol production is at its lowest.  In SEVERE cases, skin lesions may become pustular, ulcerated, hemorrhagic, necrotic , vesicular, bullous, Sweet Syndrome like and erythema multiforme-like.  Generalized systemic illness, associated with fever, myalgia, edema of face, hands and feet and loss of protein in urine are present in T2R.  Fever is considered the hallmark of ENL
  • 41.
    Erythema nodosum leprosum(ENL) in a case of LL
  • 42.
    Pustular ENL Necroticoulcerative lesionin ENL Erythema multiforme type of ENL
  • 43.
    ORGANS SIGNS ANDSYMPTOMS JOINTS Polyathritis /polyarthalgia, with pain, tenderness and limitation of movement mainly affecting knee, MCP,IP, Wrist & ankle jt. LYMPH NODES Acute and tender lymphadenopathy esp femoral, inguinal, axillary, cervical and epitrochlear LN EYES Conjunctivitis, iritis, iridocyclitis, glaucoma and blindness LIVER Hepatomegaly , soft and tender GENITILIA Epididymo-orchitis- repeated reaction can lead to testicular atrophy and gynaecomastia KIDNEYS Glomerulonephitis, acute tubulointerstitial nephritis, amylodosis- which can progress to CKD BONE Dactylitis , periosteitis MUSCLES Myalgia, myositis NERVES Neuritis
  • 44.
    DIAGNOSIS  Clinical Clinical tests: -Ryrie test : stroking of sole of foot with the back of a reflex hammer elicits a burning pain. -Ellis test : Squeezing the wrist during ENL elicits a painful reaction.  Histopathology  Laboratory tests -Haematological changes : leucocytosis, increased ESR and CRP -Urine may show presence of albumin, RBC, pus cells, epithelial cells and casts. -LFT : there may be rise in serum bilirubin and transaminases (SGOT, SGPT)
  • 45.
    CRITERIA FOR DIAGNOSISOF T2R •Proposed by B Naafs and his team •There should be presence of atleast 1 major criterion or 3 minor criteria Major criteria A sudden eruption of tender red papules, nodules or plaques which may ulcerate Minor criteria  Mild fever , the patient is unwell  Tender enlarged nerves  Increased loss of sensation and muscle power  Arthritis  Lymphadenitis  Epididymo-orchitis  Iridocyclitis or episcleritis  Edema of extermity or face  Positive Ryrie’s test or Ellis’ test
  • 46.
    MANAGEMENT GENERAL MEASURES- •Treat precipitatingfactors : -Intercurrent infections -Psychological stress. •Continue or start MDT. SPECIFIC MEASURES- 1.MILD T2R- analgesics such as aspirin, indomethacin, ibuprofen, diclofenac, paracetamol. Monitoring should be done every 2 weeks. If there is worsening and increase in symptoms, it is treated as severe. 2.MODERATE T2R- steriod is used at a dose of 30-40mg prednisolone/day. 3.RECURRENT T2R- increase and prolonged dose of steriods to control the inflammation and symptoms.
  • 47.
    TREATMENT ALGORITHM FORMANAGEMENT OF T2R
  • 48.
    1. CORTICOSTERIOD: • 1st linetreatment in severe ENL •Useful in- 1.neuritis when muscle paralysis threatened 2. iritis not responding to topical steriods 3. presence of epididymo-orchitis 4. in erythema necroticans( vesicular/bullous ENL) •Dose- 1-1.5mg/kg/day for 2-4 weeks -then tapering by 10mg every 2weeks till 20mg per day. -Then slow tapering of 5mg every 2weeks. •Patient requires steriods for long time due to reccurent and chronic nature of ENL
  • 49.
    2.THALIDOMIDE: •Treatment of choice,butkept as 2nd choice due to its teratogenic effects, difficulty in monitoring , high cost and non availability at places •MOA- 1. Inhibition of TNFα and neutrophil recruitment 2.polarization of immune response towards Th2 with production of IL2 , IL4 and 5. 3. suppresion of formation of IgM antibodies 4. decrease T helper cells and increased suppressor T cell production. •DOSE- 3-4 tabs of 100mg daily in divided doses, tailing of as reaction subsides. -continue 1tab daily or alternate day to avoid outbreaks
  • 50.
    3. CLOFAZIMINE: •High dosesof clofazimine has anti inflammatory property. •DOSE- 100 mg thrice daily along with standard course of prednisolone and to continue for a maximum of 12 weeks. - tapering of dose is 100mg twice daily for 12 weeks then 100mg once daily for 12-24 weeks. •It is slow to act and takes about 4-6 weeks to act. However it helps in reduction of dose of steriod. •Management with clofazimine alone is indicated in patient where steriods are CI.
  • 51.
    ALTERNATE OPTIONS- 1. Azathioprine– Good steriod sparing agent. It interferes with purine production , also has anti- TNFα action. - effective dose is 2mg/kg/day given for 6-8 months. 2. Methotrexate- useful in recalcitrant cases and chronic steriod resistant ENL. 3. TNFα Inhibitors- Infliximab and etanercept. - useful in resistant recurrent ENL cases which fail to respond to prednisolone. - DOSE -INFLIXIMAB at a dose of 5mg/kg, repeated dosage given on week 2 and 6. -ETANERCEPT at a dose of 50mg/week given sc
  • 52.
    4.Minocycline- has anti-inflammatoryand anti- apoptotic properties. Useful in reccurent and/or chronic cases. - main advantage of using antibacterials like minocycline and clofazimine are additional immunomodulatory, anti-inflammatory and neuroprotective action. 5. Aprimilast- oral phosphodiesterase-4 inhibitor have immunomodulatory and anti-inflammatory actions. Inhibits proinflammatory cytokines involved in T2R. 6.Leprosy Vaccine
  • 53.
    DIFFERENCES BETWEEN T1RAND T2R FEATURES T1R T2R Type of immunological reaction Delayed type of HS reaction(type IV) Antigen antibody IC reaction (type III) Type of patient affected Borderline type (BT, BB, BL, rarely subpolar LL) LL, rarely BL Constitutional signs and symptoms None or rare Common Type of skin lesions Existing skin lesions suddenly become reddish, swollen, warm, painful, tender Fresh red, painful, tender, subcutaneous nodules, plaques.Existing skin lesions remain unchanged Nerve involvement Nerves close to skin lesions may become enlarged, painful and tender due to acute neuritis with loss of nerve function Nerves may be affected but not as common or as severe as T1R Eye involvement Corneal anaesthesia and lagophthalmos may occur due to nerve involvement Internal eye diseases like iritis, iridocyclitis, glaucoma are common Other organs Not affected May be affected(lymphadenitis, epididymo-orchitis, arthritis)
  • 54.
    LUCIO PHENOMENON •This isa unique form of leprosy reaction, which occurs due to massive proliferation of lepra bacilli inside endothelial cells resulting in vascular occlusion and vasculitis. •It occurs 3-4 years after onset of disease. • It is more common in - untreated patients with diffuse LL -in those who received inadequate treatment. •It presents with minimal systemic features and neuritis.
  • 55.
    LESIONS Painful, tender, redpatch, with a geographic margin Becomes purpuric Center becomes necrotic and ulcerate Develops brown or black crust (eschar) Falls off after few days to leave a superficial atrophic scar
  • 56.
    ETIOPATHOGENESIS Patients in luciophenomenon has a singularly deficient defense mechanism Which permits unhindered multiplication of bacteria Exposure of bacterial antigen to circulating antibody Vasculitis, thrombosis, infarction and skin necrosis HISTOLOGY - Ischaemic epidermal necrosis, •Fibrin thrombi in vessel lumen with wall infiltration, necrotising vasculitis of small and medium blood vessels in the upper dermis •severe focal endothelial proliferation of mid-dermal vessels •presence of large number of AFB in endothelial cells.
  • 57.
    CLINICAL FEATURE •Patient isusually afebrile •Appearance of erythematous diffuse or plaque type lesions which becomes purpuric, becomes necrotic followed by black eschar formation. •The lesions mainly appear on the extremities and spreads in a characteristic ascending fashion. •The lesions are frequently described as triangular, polygonal or angular ulcers. •Occasionally hemorrhagic blisters and edema of hands, feet and ear conchae have been described •Usually patient have lesions which are on different stages of evolution. TREATMENT • MDT should be started. • Respond well to oral steroids. Do not respond to thalidomide .
  • 58.
  • 59.
    LUCIO PHENOMENON VsT2R WITH VASCULONECROTIC PHENOMENON FEATURES LUCIO PHENOMENON NECROTIZING ENL Seen in Diffuse LL BL, LL Patient status Untreated Treated Clinical features Angular geographic necrotic lesions, ulcers,heals with scar Generalized Painful nodules with necrosis Histology Inv. of medium sized vessels of mid dermis with thrombosis and endothelial proliferation. Necrotizing vasculitis of small blood vessels of superficial dermis Panvasculitis starts in hypodermis with larger deep necrosis resulting in fibrotic scar. General symptoms No general symptoms Systemic features with fever seen Neuritis Absent Marked Mainly vasculopathy Vasculitis
  • 60.
    LAZARINE LEPROSY It isulcerating type 1 reaction •Found in BT Hansen with spontaneous ulceration, occuring due to extreme hypersensitivity in type 1 reaction •Factors implicated- breakdown of local immunity, increase proliferation of bacilli and severe tissue edema. •Concomitant secondary infection due to protein malnutrition have also been implicated. •There is no localized skin infiltrations. •Systemic corticosteriods are necessary.
  • 61.
    Multiple non tenderulcers appearing on pre-existing lesion of chest and back
  • 62.